Michelle Murti appointed Toronto's new medical officer of health
Her start on Sept. 3 is subject to the approval of the province's Ministry of Health.
Dr. Murti currently serves as associate chief medical officer of health for Ontario.
"She has played a pivotal role in pandemic preparedness, emergency response and health system transformation," the city said in a news release Wednesday.
Dr. Murti has a medical degree, a public health Master's degree and is a fellow of the Royal College of Physicians and Surgeons of Canada in public health and preventive medicine.
She is also licensed in family medicine and serves as an adjunct professor at the University of Toronto's Dalla Lana School of Public Health.
"Under Dr. Murti's leadership, Toronto Public Health will continue to build on its legacy of innovation, resilience and impact as one of Canada's leading local public health agencies," the city said.
Dr. Murti says she is honoured to be taking on this role.
"I look forward to working alongside the incredible Toronto Public Health staff and with community and city partners to protect and improve health, reduce health inequities and make Toronto a healthy and resilient place where we can all live, work and play," she said in the release.
Toronto Mayor Olivia Chow said this move is a step forward.
"I am confident that Dr. Murti is well-prepared to take on the top leadership role for Toronto Public Health in its service to our residents," she said in the release.
Dr. Na-Koshie Lamptey will continue to serve as Toronto's acting medical officer of health until Sept. 2.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
8 minutes ago
- Washington Post
Senate to vote on Trump's pick to lead the CDC
The Senate is scheduled to vote Tuesday on confirming longtime federal government scientist Susan Monarez to lead the Centers for Disease Control and Prevention, the public health agency that is under intense scrutiny as Robert F. Kennedy Jr. upends vaccine policy in the United States. Monarez, President Donald Trump's second pick for the job, is expected to be confirmed because Republicans who control the chamber have not expressed opposition to her nomination.
Yahoo
an hour ago
- Yahoo
Millions in Europe unknowingly living with hepatitis, health authorities warn
Millions of people across Europe are living with hepatitis B or C without knowing it, putting them at serious risk of liver disease and cancer, public health authorities have warned. The European Centre for Disease Prevention and Control (ECDC) said in a new report that around five million people in the European Union, Iceland, Liechtenstein, and Norway are living with chronic hepatitis B or C – but the majority are undiagnosed and untreated. Often referred to as 'silent infections', hepatitis B and C can live undetected in the body for years, slowly damaging the liver until symptoms appear in the form of liver fibrosis (scarring), cirrhosis, or cancer. The virus is typically spread through contact with infected blood or bodily fluids, including through unprotected sex or shared drug equipment. The report estimates that 3.2 million people in the region are infected with hepatitis B, and 1.8 million have hepatitis C. Together, these viruses are linked to roughly 50,000 deaths every year. Related 'I was scared': Half of Europeans living with hepatitis struggle to tell others about diagnosis Hepatitis A is spreading rapidly in the Czech Republic with 6 deaths so far. Here's what we know 'We must underline the critical importance of scaling up efforts to prevent and control viral hepatitis," Dr Marieke van der Werf, the head of the ECDC's section on blood-borne viruses and tuberculosis, said in a statement. She said access to vaccination, testing, and medical care for infected people "are essential for a healthier, more resilient Europe". According to the ECDC, more than 65 per cent of those with hepatitis B and 62 per cent of those with hepatitis C are still undiagnosed. Hepatitis C can be cured with a short course of highly effective antiviral medications. While hepatitis B cannot currently be cured, it can be managed with long-term treatment that helps suppress the virus and reduce the risk of liver damage. Meanwhile, hepatitis A, which spreads via infected stool, is an acute infection that typically resolves on its own. Globally, chronic viral hepatitis causes an estimated 1.3 million deaths each year. That's around 3,500 deaths every day, putting it on par with tuberculosis (TB). The World Health Organization says 2.8 million of these deaths could be prevented by 2030, and has called on governments to embed hepatitis screening and treatment into primary healthcare, especially for vulnerable and high-risk communities.
Yahoo
an hour ago
- Yahoo
North America Clinical Trials Market Forecast and Company Analysis Report 2025-2033 Featuring ICON, Wuxi AppTec, SGS, Syneos Health, PRA Health Sciences, Pfizer, IQVIA, and Medpace
The North America Clinical Trials Market is projected to grow from US$ 20.07 billion in 2024 to US$ 33.91 billion by 2033, registering a CAGR of 6.00% from 2025 to 2033. Key drivers include the increasing demand for novel treatments, rising prevalence of chronic conditions like COVID-19, diabetes, and various cancers, as well as supportive government R&D investments. The U.S. leads with robust infrastructure, top-notch research facilities, and significant technological advancements such as AI and decentralized trials. However, challenges persist with high operational costs and regulatory complexities. The market is vibrant, driven by rising clinical trial investments in sectors like oncology and enabled by innovative technologies, making it a promising field despite ongoing hurdles. North American Clinical Trials Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "North America Clinical Trials Market Size and Forecast Report 2025-2033" report has been added to North America Clinical Trials Market is expected to reach US$ 33.91 billion by 2033 from US$ 20.07 billion in 2024, with a CAGR of 6.00% from 2025 to 2033. This is explained by longer clinical trial cycles, the demand for new treatments, and an increase in viral disorders as COVID-19 and diabetes, as well as advantageous government R&D spending. The growing need for novel medicines in a variety of therapeutic areas, including neurology, cardiology, and oncology, is the main factor propelling the North American clinical trials market's constant expansion. As a market leader, the United States enjoys the advantages of strong infrastructure, top-notch research facilities, and substantial investments in innovative healthcare. Drug development procedures are becoming faster and more efficient because to technological developments like big data, artificial intelligence, and decentralized clinical trials. Government financing and support for clinical research also contribute to the market's expansion. Nonetheless, the sector is still affected by issues including regulatory barriers, trouble recruiting patients, and expensive trial operating expenses. The market is nevertheless vibrant and is anticipated to continue evolving in spite of these market will expand quickly as a result of the growing number of clinical trials in North America, the pharmaceutical industry's expensive R&D costs, and the rising incidence of illnesses. Clinical trials for new or uncommon diseases are anticipated to benefit from the diverse disease profiles that are found to be growing with time due to the growing population in the North American region. Therefore, biopharmaceutical companies would be encouraged to increase their investment in clinical trials for a particular disease segment based on the number of patients with that of September 2022, there were over 13,323 ongoing clinical studies in various stages for cancer indications in the US, according to the US National Library of Medicine. Over the past few years, pharmaceutical corporations have likewise been spending more and more on research and development (R&D). This was mostly caused by a large number of patents expiring, which leaves many pharmaceutical companies with no choice except to create new medications. As a result, businesses are investing more in R&D to speed up the creation of medications through clinical trials, which will increase the market as a Drivers for the North America Clinical Trials Market Rising Prevalence of Chronic DiseasesOne of the main factors propelling the North American clinical trials market's expansion is the growing incidence of chronic illnesses including diabetes, cancer, and cardiovascular disorders. Clinical trials are being conducted by pharmaceutical corporations and research institutions due to the growing demand for new treatments and therapies as these diseases proliferate. These studies are essential for assessing the efficacy and security of possible treatments. Clinical trials are crucial for expanding medical knowledge and enhancing patient outcomes since chronic diseases frequently call for long-term management and innovative treatment choices. An older population, which is more likely to suffer chronic illnesses, supports this trend and increases the need for ongoing clinical research and innovative therapy in TechnologyTechnological developments are drastically changing the clinical trials environment in North America. Clinical study design, management, and execution are being improved by emerging technologies including artificial intelligence (AI), machine learning (ML), and big data analytics. These technologies aid in the real-time analysis of massive volumes of trial data, the more accurate identification of qualified applicants, and the prediction of patient outcomes. They thereby shorten trial durations, cut down on mistakes, and enhance decision-making. AI and ML are also being used to remotely monitor patient adherence and optimize protocol design, which lowers costs and increases trial efficiency. These developments make technology a potent growth engine in the dynamic clinical research environment since they not only speed up drug development but also increase trial success Investment in Oncology ResearchOne of the main factors propelling the growth of the clinical trials market is the rising incidence of cancer in North America, which has greatly increased funding for oncology research. The creation of novel cancer treatments is receiving a significant amount of support from public and private institutions as well as pharmaceutical firms. Clinical trials focusing on cancer, such as immunotherapies, targeted medicines, and personalized medical methods, have increased as a result of this financial boom. Research efforts have been sped up by the need to find efficient treatments and raise survival rates, which has prompted quicker trial initiation and increased cooperation between sponsors and research institutes. Since cancer is still one of the top causes of mortality, the region's clinical trial activity is growing in scope and size due to the strong emphasis on oncology in the North America Clinical Trials Market High Operational CostsOne major issue facing the clinical trials sector in North America is high operating costs. Significant costs are associated with conducting a clinical trial, such as hiring highly qualified personnel, investing in cutting-edge technology, building out the facility, adhering to regulations, and continuously gathering and tracking data. Complex trial designs, multi-site coordination, and longer study durations can all result in further increases in these expenses. Financial limitations can make it difficult for smaller biotech companies and research institutes to start or continue trials, frequently forcing them to rely on collaborations or outside funding. There is still a lot of pressure to strike a balance between cost effectiveness, data quality, and legal requirements. The cost of trials only goes up as they get more creative and customized, which is a major obstacle to larger research and development ComplexitiesOne of the biggest obstacles facing the clinical trials sector in North America is the complexity of regulations. To guarantee the safety and effectiveness of novel medications and therapies, organizations such as the U.S. Food and Drug Administration (FDA) implement strict and ever-changing regulations. Although these rules are necessary, following them can cause delays in trial approvals and raise compliance expenses dramatically. The procedure, which can be time- and resource-intensive, entails thorough documentation, ethical evaluations, and adherence to stringent criteria. Conducting multinational or multi-site studies also adds another level of complexity because different regulatory requirements in different locations need to be carefully maintained. These elements may cause delays in the start of trials, cause schedule disruptions, and increase the administrative load on sponsors and research institutions. Key Players Analyzed: Overviews, Key Persons, Recent Developments, Revenue ICON Plc Wuxi AppTec SGS SA Syneos Health PRA Health Sciences Inc Pfizer Inc. IQVIA Medpace Stryker Corporation Zimmer Biomet Holdings Orthofix Medical Inc. NuVasive Inc. Globus Medical Inc. Bejo Zaden BV Corteva Agriscience Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $20.07 Billion Forecasted Market Value (USD) by 2033 $33.91 Billion Compound Annual Growth Rate 6.0% Regions Covered North America Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. North America Clinical Trials Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share6.1 By Phases6.2 By Indications6.3 By Study Designs6.4 By Countries7. Phases7.1 Phase 17.2 Phase 27.3 Phase 37.4 Phase 48. Indications8.1 Autoimmune/Inflammation8.2 Pain management8.3 Oncology8.4 CNS Condition8.5 Diabetes8.6 Obesity8.7 Cardiovascular8.8 Others9. Study Designs9.1 Interventional9.2 Observational9.3 Expanded Access10. Countries10.1 United States10.2 Canada10.3 Mexico10.4 Rest of North America11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players AnalysisFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment North American Clinical Trials Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
